{"schema_version":"secwatch.filing_event.v1","accession":"0001818331-23-000066","form_type":"8-K","ticker":"WGS","cik":"0001818331","company_name":"GeneDx Holdings Corp.","filed_at":"2023-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.646739+00:00","generated_at":"2026-06-09T06:11:13.440402+00:00","sec_items":["1.01","1.02","2.02","2.03","3.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"GeneDx Q3: revenue $53M, exome/genome up 42% YoY; cuts FY rev guidance to $187-192M; secures $75M Perceptive debt","bullets":["Continuing ops revenue $50.4M; exome and genome test revenue $34M (+42% YoY). Adjusted gross margin from cont ops 48%.","Net loss $42.3M; adjusted net loss $21.2M, improved 70% YoY. Cash burn $42M, down 51% YoY.","FY2023 revenue guidance lowered to $187-192M (from $205-220M). Path to profitability in 2025 reiterated.","Entered $75M senior secured credit facility with Perceptive Advisors; initial $50M funded at SOFR+7.5%. Warrants for 800k shares at $3.17.","Enacted $40M annual cost savings plan including ~10% workforce reduction. Appointed Melanie Duquette as Chief Growth Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001818331-23-000066","json":"https://secwatch.observer/filing/0001818331-23-000066.json","markdown":"https://secwatch.observer/filing/0001818331-23-000066.md","text":"https://secwatch.observer/filing/0001818331-23-000066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818331/000181833123000066/0001818331-23-000066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818331/000181833123000066/wgs-20231027.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T06:11:13.440402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"78448ca9eee1f9f49eeb7211af59efd33be01ecf","claim":"GeneDx Holdings Corp. incurred term loan of up to $75.0 million with Perceptive Credit Holdings IV, LP at Term SOFR plus 7.5% maturing October 27, 2028.","evidence_excerpt":"GeneDx Holdings Corp. (the “Company”) entered into a Credit Agreement and Guaranty (the “Credit Agreement”) with Perceptive Credit Holdings IV, LP, as lender and administrative agent (“Perceptive”), which provides for a senior secured delayed draw term loan facility in an aggregate principal amount of up to $75.0 million","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818331/000181833123000066/0001818331-23-000066-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"up to $75.0 million"},{"label":"Counterparty","value":"Perceptive Credit Holdings IV, LP"},{"label":"Rate","value":"Term SOFR plus 7.5%"},{"label":"Maturity","value":"October 27, 2028"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"664223a32b7e5ebd0bc1a9ce64e8693faf687127","claim":"GeneDx Holdings Corp. reported the third quarter of 2023 results: revenue $53.3 million, net income $42.3 million. Guidance lowered.","evidence_excerpt":"for the third quarter of 2023 narrowed to $21.2 million 2 , an improvement of 70% year-over-year and 45% sequentially. • Revenue 1 : Revenue for the third quarter of 2023 was $53.3 million, compared to $83.2 million in the third quarter of 2022. • Gross Margin 1 : Gross margin for the third quarter of 2023 was 47%. Adjusted gross margin for the third quarter of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818331/000181833123000066/0001818331-23-000066-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2023"},{"label":"Revenue","value":"$53.3 million"},{"label":"Net income","value":"$42.3 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b380d6d005eeb423611aa4ea22da75d04e491b4e","claim":"GeneDx Holdings Corp. entered into Credit Agreement and Guaranty with Perceptive Credit Holdings IV, LP valued at up to $75.0 million (effective 2023-10-27).","evidence_excerpt":"On October 27, 2023 (the \"Closing Date\"), GeneDx Holdings Corp. (the \"Company\") entered into a Credit Agreement and Guaranty (the \"Credit Agreement\") with Perceptive Credit Holdings IV, LP, as lender and administrative agent (\"Perceptive\"), which provides for a senior secured delayed draw term loan facility in an aggregate principal amount of up to $75.0 million","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818331/000181833123000066/0001818331-23-000066-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Perceptive Credit Holdings IV, LP"},{"label":"Value","value":"up to $75.0 million"},{"label":"Effective","value":"2023-10-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}